)
)
HilleVax Investor Relations Material
Latest events
Access the full event backlog
Slides, Transcripts, and Reports from 12,000+ public companies
Latest reports from HilleVax Inc
Access all reports
HilleVax, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines. The company’s primary product under development is HIL-214, a virus-like particle-based vaccine candidate aimed at preventing moderate-to-severe acute gastroenteritis caused by norovirus infection. HilleVax has been working on advancing this vaccine through clinical trials, with efforts to evaluate its safety and efficacy across different age groups. Hillevax is headquartered in Boston, Massachusetts, and its shares are listed on the NASDAQ.
Key slides for HilleVax Inc
Corporate Presentation
HilleVax Inc
Corporate Presentation
HilleVax Inc
Latest articles
)
Quartr Brings Stories Behind the Numbers to Light
Quartr simplifies access to IR material and puts qualitative insights and company narratives front and center.
3 Feb 2025
)
The Evolution of the IRO Role: Staying Informed and Strategic With Quartr Pro
Staying informed is critical for IROs. Quartr Pro simplifies gathering market insights and narrative positioning with unprecedented speed and precision.
3 Feb 2025
)
Mips: The Gore-Tex of Brain Protection
How Mips turned a critical safety flaw into a global success, redefining helmet protection with its technology and ingredient brand business model.
24 Jan 2025
Ticker symbol
HLVX
Country
🇺🇸 United States